S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NYSE:CRL

Charles River Laboratories International (CRL) Stock Forecast, Price & News

$235.81
+9.10 (+4.01%)
(As of 05/13/2022 06:40 PM ET)
Add
Compare
Today's Range
$232.01
$239.59
50-Day Range
$222.31
$302.40
52-Week Range
$217.20
$460.21
Volume
470,200 shs
Average Volume
563,488 shs
Market Capitalization
$11.98 billion
P/E Ratio
28.72
Dividend Yield
N/A
Beta
1.27
30 days | 90 days | 365 days | Advanced Chart
Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

Charles River Laboratories International logo

About Charles River Laboratories International

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Headlines

S&P 500 Movers: CRL, DISCK
What 6 Analyst Ratings Have To Say About Charles River
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
15986410
Employees
20,000
Year Founded
1947

Sales & Book Value

Annual Sales
$35.40 billion
Cash Flow
$15.77 per share
Book Value
$51.47 per share

Profitability

Net Income
$390.98 million
Pretax Margin
14.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
50,246,000
Market Cap
$11.98 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/16/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.61 out of 5 stars

Medical Sector

87th out of 1,403 stocks

Commercial Physical Research Industry

3rd out of 23 stocks

Analyst Opinion: 4.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Charles River Laboratories International (NYSE:CRL) Frequently Asked Questions

Is Charles River Laboratories International a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International
or view top-rated stocks.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Charles River Laboratories International
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings results on Wednesday, May, 4th. The medical research company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.71 by $0.04. The medical research company earned $913.93 million during the quarter, compared to the consensus estimate of $908.64 million. Charles River Laboratories International had a trailing twelve-month return on equity of 21.90% and a net margin of 11.64%. The company's quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.53 earnings per share.
View Charles River Laboratories International's earnings history
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $11.50-$11.75 for the period, compared to the consensus earnings per share estimate of $11.64. The company issued revenue guidance of $4.02 billion-$4.09 billion, compared to the consensus revenue estimate of $4.02 billion.

What price target have analysts set for CRL?

15 brokerages have issued 12-month price targets for Charles River Laboratories International's stock. Their forecasts range from $280.00 to $480.00. On average, they expect Charles River Laboratories International's share price to reach $385.21 in the next twelve months. This suggests a possible upside of 63.4% from the stock's current price.
View analysts' price targets for Charles River Laboratories International
or view top-rated stocks among Wall Street analysts.

Who are Charles River Laboratories International's key executives?
Charles River Laboratories International's management team includes the following people:
What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.68%), BlackRock Inc. (10.29%), Clearbridge Investments LLC (2.69%), Massachusetts Financial Services Co. MA (2.25%), William Blair Investment Management LLC (2.04%) and Mackenzie Financial Corp (1.69%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends for Charles River Laboratories International
.

Which major investors are selling Charles River Laboratories International stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., Raymond James & Associates, First Trust Advisors LP, National Pension Service, State of Tennessee Treasury Department, and KBC Group NV. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Victoria L Creamer, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International
or view top insider-selling stocks.

Which major investors are buying Charles River Laboratories International stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Clearbridge Investments LLC, BlackRock Inc., Montrusco Bolton Investments Inc., Baird Financial Group Inc., Riverbridge Partners LLC, Vanguard Group Inc., and Bellevue Group AG.
View insider buying and selling activity for Charles River Laboratories International
or or view top insider-buying stocks.

How do I buy shares of Charles River Laboratories International?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $235.81.

How much money does Charles River Laboratories International make?

Charles River Laboratories International has a market capitalization of $11.98 billion and generates $35.40 billion in revenue each year. The medical research company earns $390.98 million in net income (profit) each year or $8.21 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

Charles River Laboratories International employs 20,000 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..

When was Charles River Laboratories International founded?

Charles River Laboratories International was founded in 1947.

What is Charles River Laboratories International's official website?

The official website for Charles River Laboratories International is www.criver.com.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at (781) 222-6000, via email at [email protected], or via fax at 978-988-5665.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.